Adler Lenard A
Department of Psychiatry and Child and Adolescent Psychiatry, New York University School of Medicine and NYU Langone Medical Center, and Psychiatry Service, VA Harbor Healthcare System, NY, USA.
J Clin Psychiatry. 2009 May;70(5):e12. doi: 10.4088/jcp.7129br5c.
The U.S. Food and Drug Administration has approved 3 medications, atomoxetine and the extended-release formulations of amphetamine salts and dexmethylphenidate, for the treatment of adult attention-deficit hyperactivity disorder (ADHD). Different formulations of the same drugs, as well as other agents and cognitive-behavioral therapy, have been tested to determine efficacy in ADHD alone and in ADHD with comorbid substance use disorders, mood disorders, and anxiety disorders. A deficit in research exists in regard to these comorbidities in adults with ADHD.
美国食品药品监督管理局已批准三种药物用于治疗成人注意力缺陷多动障碍(ADHD),即托莫西汀以及苯丙胺盐和右哌甲酯的缓释制剂。已对相同药物的不同剂型以及其他药物和认知行为疗法进行了测试,以确定其单独治疗ADHD以及治疗合并物质使用障碍、情绪障碍和焦虑障碍的ADHD的疗效。在患有ADHD的成人中,针对这些共病情况的研究存在不足。